Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Clinical trial NCT06454968 · RECRUITING
Trial details
- NCT number
- NCT06454968
- Sponsor
- Peking Union Medical College Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-20
- Primary completion
- 2026-06-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.